Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says. Though most people recover from the ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

In sixty years of career, he spoke about racism, religion, sex, hunger, death penalty, war, anorexia, violence. The ...

McKinsey & Company’s prestigious two-day workshop Bower Forum is a unique platform for a small group of CEOs or Chairpersons ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Adjusted per-share earnings in the fourth quarter for UnitedHealth top analysts’ estimates but revenue comes up short.

The Nasdaq-100 Index® is composed of 100 of the largest non-financial c CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the ...

Yahoo Finance's Brad Smith reviews Wednesday's trending stocks on Wealth. Moderna's (MRNA) price target slashed to $38 from $70 by Morgan Stanley (MS), implying an 11% potential upside based on ...

Elon Musk could target the F-35 when looking for savings at his newly created quasi-government consultancy Department of ...

Wednesday's Forbes Daily features a promising norovirus vaccine, Trump's proposed "External Revenue Service," TikTok's price ...